{"disease":{"id":"triple-negative-breast-neoplasms","name":"Triple negative breast neoplasms","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"sacituzumab-govitecan","indication_name":"Triple negative breast neoplasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trodelvy","generic_name":"sacituzumab-govitecan","company_name":"Immunomedics Inc","drug_phase":"marketed","molecular_target":"Tumor-associated calcium signal transducer 2","drug_class":"","quality_score":68,"revenue":"800","mechanism":"Trodelvy works by binding to the TACI receptor on cancer cells, triggering a cascade of events that ultimately leads to cell death."},{"drug_id":"pembrolizuma","indication_name":"Triple negative breast neoplasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06966700","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03036488","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1174,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06841354","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03997123","title":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":923,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03371017","title":"A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":595,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04191135","title":"Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01969643","title":"A Safety Study of SGN-LIV1A in Breast Cancer Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT05194072","title":"A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":250,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03742102","title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":243,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03539965","title":"Triple-negative Breast Cancer: a New Perspective on Biomarkers","phase":"","overall_status":"COMPLETED","enrollment_count":239,"lead_sponsor_name":"Instituto Nacional de Cancer, Brazil","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT03310957","title":"Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"Seagen Inc.","has_results":true},{"nct_id":"NCT03396445","title":"Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT02124902","title":"Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":148,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04251533","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":137,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT05067530","title":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Medical University of Gdansk","has_results":false},{"nct_id":"NCT05544929","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04596150","title":"Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"CytomX Therapeutics","has_results":false},{"nct_id":"NCT02978716","title":"Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"G1 Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03818685","title":"Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":95,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06154109","title":"Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Zhiyu Wang","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT02622074","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04504669","title":"First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06385990","title":"Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":53,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT02834247","title":"A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":true},{"nct_id":"NCT04879849","title":"A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05435352","title":"Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment","phase":"","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"Ourotech, Inc.","has_results":false},{"nct_id":"NCT02658214","title":"Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06246968","title":"A Study of Pembrolizumab and Cryoablation in People With Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03692689","title":"Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT03225547","title":"Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05485766","title":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":23,"lead_sponsor_name":"Okayama University","has_results":false},{"nct_id":"NCT06264921","title":"A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02299635","title":"A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02348320","title":"Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03199040","title":"Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT02938442","title":"Vaccination of Triple Negative Breast Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"University of Arkansas","has_results":true},{"nct_id":"NCT03092934","title":"A Study of AK-01 (LY3295668) in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04489940","title":"Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT03838367","title":"Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"CytoDyn, Inc.","has_results":true},{"nct_id":"NCT05451849","title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"TCR2 Therapeutics","has_results":false},{"nct_id":"NCT02720185","title":"Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true},{"nct_id":"NCT04123704","title":"Sitravatinib in Metastatic Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Xiang Zhang","has_results":true},{"nct_id":"NCT06067061","title":"\"neoBREASTIM\": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Institut Curie","has_results":false}],"total":50},"guidelines":[{"drug_id":"sacituzumab-govitecan","guideline_body":"FDA label","recommendation":"TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.","line_of_therapy":"3L+","evidence_grade":"not specified","guideline_year":null},{"drug_id":"sacituzumab-govitecan","guideline_body":"FDA label","recommendation":"TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","line_of_therapy":"3L+","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}